One cisplatin dose provides durable stimulation of anti-tumor immunity and alleviates anti-PD-1 resistance in an intraductal model for triple-negative breast cancer

Aggressive triple-negative breast cancer (TNBC) is classically treated with chemotherapy. Besides direct tumor cell killing, some chemotherapeutics such as cisplatin provide additional disease reduction through stimulation of anti-tumor immunity. The cisplatin-induced immunomodulation in TNBC was he...

Descripción completa

Detalles Bibliográficos
Autores principales: Steenbrugge, Jonas, Bellemans, Julie, Vander Elst, Niels, Demeyere, Kristel, De Vliegher, Josephine, Perera, Timothy, De Wever, Olivier, Van Den Broeck, Wim, De Spiegelaere, Ward, Sanders, Niek N., Meyer, Evelyne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311321/
https://www.ncbi.nlm.nih.gov/pubmed/35898705
http://dx.doi.org/10.1080/2162402X.2022.2103277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311321/
https://www.ncbi.nlm.nih.gov/pubmed/35898705
http://dx.doi.org/10.1080/2162402X.2022.2103277

Ejemplares similares